In NHL patients who benefit from CD19 CAR T cell therapy, despite prevalent adverse events (AEs), such as cytokine release syndrome (CRS), the most prominent problem from the perspective of long-term clinical efficacy is recurrence after remission [20–22]. The gene discussed is CD19; the disease is non-Hodgkin lymphoma.